Payment overview · 2025
General Payments
$1,976.32
109 reported records · 19 companies
Healthcare provider profile · identity verified
Mark R Akerson, MD
Allopathic & Osteopathic Physicians|Family Medicine · MARIANNA, FL · NPI 1699720367
Verified facts
What the public records show
CMS Open Payments records show Mark R Akerson, MD received $1,976.32 in general payments during 2025 across 109 reported records.
ABBVIE INC. accounted for 16.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $326.02 | 16.5% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $287.23 | 14.5% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $257.06 | 13.0% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $199.80 | 10.1% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $184.21 | 9.3% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $173.13 | 8.8% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $161.14 | 8.2% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.87 | 3.8% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $60.81 | 3.1% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $48.42 | 2.5% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $45.79 | 2.3% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.34 | 1.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.15 | 1.2% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $20.40 | 1.0% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $19.00 | 1.0% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $17.36 | 0.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.12 | 0.9% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.45 | 0.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.02 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,976.32 | 109 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $277.50 | 15 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $218.82 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $199.80 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $199.80 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $184.21 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $161.14 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $151.65 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $123.97 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $120.13 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $99.55 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $88.62 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $83.20 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $68.31 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $63.72 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $60.81 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $48.42 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $45.79 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.65 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.25 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $29.34 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $9.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 136 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 58 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 100 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 90 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
136 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
90 | 20 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
100 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
244 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 540 | 88 |
| Atorvastatin Calcium | Atorvastatin Calcium | 538 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 509 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 466 | 103 |
| Losartan Potassium | Losartan Potassium | 418 | 102 |
| Gabapentin | Gabapentin | 368 | 83 |
| Furosemide | Furosemide | 330 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 312 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 287 | 78 |
| Potassium Chloride | Potassium Chloride | 269 | 75 |
| Lisinopril | Lisinopril | 264 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 254 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 245 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 245 | 72 |
| Eliquis | Apixaban | 244 | 39 |
| Montelukast Sodium | Montelukast Sodium | 233 | 60 |
| Donepezil Hcl | Donepezil Hcl | 222 | 39 |
| Metformin Hcl | Metformin Hcl | 217 | 59 |
| Omeprazole | Omeprazole | 217 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 211 | 54 |
| Trazodone Hcl | Trazodone Hcl | 201 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 196 | 51 |
| Carvedilol | Carvedilol | 194 | 45 |
| Mounjaro | Tirzepatide | 186 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 173 | 46 |
| Tramadol Hcl | Tramadol Hcl | 156 | 49 |
| Alprazolam | Alprazolam | 153 | 32 |
| Buspirone Hcl | Buspirone Hcl | 148 | 44 |
| Januvia | Sitagliptin Phosphate | 148 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 148 | 45 |
| Celecoxib | Celecoxib | 147 | 46 |
| Allopurinol | Allopurinol | 141 | 46 |
| Famotidine | Famotidine | 141 | 46 |
| Farxiga | Dapagliflozin Propanediol | 136 | 22 |
| Clonidine Hcl | Clonidine Hcl | 128 | 53 |
| Simvastatin | Simvastatin | 126 | 32 |
| Memantine Hcl | Memantine Hcl | 125 | 20 |
| Sucralfate | Sucralfate | 119 | 29 |
| Levetiracetam | Levetiracetam | 116 | 22 |
| Meloxicam | Meloxicam | 116 | 27 |
| Alendronate Sodium | Alendronate Sodium | 114 | 31 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 109 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 109 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 102 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 100 | 23 |
| Ozempic | Semaglutide | 100 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 98 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 95 | 20 |
| Sertraline Hcl | Sertraline Hcl | 94 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 92 | 28 |
| Spironolactone | Spironolactone | 91 | 20 |
| Clonazepam | Clonazepam | 90 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 90 | 20 |
| Xarelto | Rivaroxaban | 90 | 13 |
| Mirtazapine | Mirtazapine | 88 | 21 |
| Valsartan | Valsartan | 87 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 86 | 24 |
| Levofloxacin | Levofloxacin | 79 | 60 |
| Prednisone | Prednisone | 77 | 38 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 70 | 15 |
| Pregabalin | Pregabalin | 70 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 69 | 17 |
| Entresto | Sacubitril/Valsartan | 68 | 17 |
| Bumetanide | Bumetanide | 66 | 20 |
| Fluconazole | Fluconazole | 66 | 35 |
| Glimepiride | Glimepiride | 61 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 22 |
| Methylphenidate Hcl | Methylphenidate Hcl | 60 | suppressed |
| Nifedipine Er | Nifedipine | 60 | 17 |
| Methocarbamol | Methocarbamol | 59 | 25 |
| Myrbetriq | Mirabegron | 59 | 11 |
| Jardiance | Empagliflozin | 58 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 16 |
| Morphine Sulfate Er | Morphine Sulfate | 58 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 16 |
| Atenolol | Atenolol | 57 | 12 |
| Cefdinir | Cefdinir | 57 | 50 |
| Glipizide Er | Glipizide | 57 | 14 |
| Meclizine Hcl | Meclizine Hcl | 57 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 14 |
| Cephalexin | Cephalexin | 52 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 12 |
| Labetalol Hcl | Labetalol Hcl | 51 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 13 |
| Finasteride | Finasteride | 48 | 12 |
| Glipizide | Glipizide | 48 | 16 |
| Baclofen | Baclofen | 47 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 37 |
| Nystatin | Nystatin | 47 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 12 |
| Vraylar | Cariprazine Hcl | 46 | suppressed |
| Ezetimibe | Ezetimibe | 43 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 15 |
| Temazepam | Temazepam | 42 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 41 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | suppressed |
| Azithromycin | Azithromycin | 38 | 30 |
| Colesevelam Hcl | Colesevelam Hcl | 38 | suppressed |
| Permethrin | Permethrin | 38 | 34 |
| Topiramate | Topiramate | 38 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Novolog Flexpen | Insulin Aspart | 37 | 13 |
| Belsomra | Suvorexant | 36 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 34 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Mupirocin | Mupirocin | 32 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 26 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 19 |
| Ondansetron Odt | Ondansetron | 30 | 18 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 25 |
| Linzess | Linaclotide | 29 | suppressed |
| Xifaxan | Rifaximin | 28 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Pentoxifylline | Pentoxifylline | 24 | suppressed |
| Scopolamine | Scopolamine | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 22 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 21 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 21 | suppressed |
| Linezolid | Linezolid | 21 | 16 |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Livalo | Pitavastatin Calcium | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 15 |
| Naproxen | Naproxen | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 14 |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Budesonide | Budesonide | 16 | suppressed |
| Colchicine | Colchicine | 16 | 12 |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Ertapenem | Ertapenem Sodium | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,976.32 · 109 records | ABBVIE INC. | AIRSUPRA, AREXVY, Ambulatory Monitoring & Diagnostics Undivided, BREZTRI, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, EVENITY, FANAPT, FARXIGA, FUROSCIX, JARDIANCE, JASCAYD, JOURNAVX, Kerendia, LEQVIO, NURTEC ODT, OFEV, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, Qelbree, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error